Clinical relevance of cytogenetics in myelodysplastic syndromes

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 395-410

  Bernasconi, Paolo ^a   Boni, Marina ^a   Cavigliano, Paola Maria ^a   Calatroni, Silvia ^a   Giardini, Ilaria ^a   Rocca, Barbara ^a   Zappatore, Rita ^a   Dambruoso, Irene ^a   Caresana, Marilena ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chromosomal abnormalities; FAB subtype; Fluorescence in situ hybridization; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; THALIDOMIDE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 12P; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 17; CHROMOSOME 20Q; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION Y; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; CYTOGENETICS; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PROGNOSIS; STEM CELL; SURVIVAL; TRISOMY 8; WORLD HEALTH ORGANIZATION; Y CHROMOSOME; CHROMOSOME 7; GENETICS; MORTALITY; PATHOLOGY; REVIEW; ULTRASTRUCTURE;

CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; CYTOGENETICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 33847772851     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.034     Document Type: Conference Paper

References (18)

1. HEANY, M.L. et al. 1999. Myelodysplasia. N. Engl. J. Med. 340: 1649-1653.
2. BENNET, J.M. et al. 1976. Proposals for the classification of the acute leukemias (FAB cooperative group). Br. J. Haematol. 33: 451-458.
3. HARRIS, N.L. et al. 1999. World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J. Clin. Oncol. 17: 3835-3849.
4. VAN DEN BERGHE H. et al. 1974. Distinct haematological disorder with deletion of the long arm of no. 5 chromosome. Nature 251: 437-438.
5. MUFTI, G.J. et al. 1985. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 59: 425-433.
6. SANZ, G.F. et al. 1989. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74: 395-408.
7. AUL, C. et al. 1992. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia 6: 52-59.
8. MOREL P. et al. 1993. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7: 1315-1323.
9. GREENBERG, P. et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
10. SOLÈ, F. et al. 2000. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br. J. Haematol. 108: 346-356.
11. GIAGOUNIDIS, A.A.N. et al. 2004. Clinical, morphological, cytogenetic, and prognostic features of patients withmyelodysplastic syndromes and del(5q) including band q31. Leukemia 18: 113-119.
12. BERNASCONI, P. et al. 2005. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19: 1424-1431.
13. SOLÈ, F. et al. 2005. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90: 1168-1178.
14. MALCOVATI, L. et al. 2005. Prognostic factors and life expectancy inmyelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23: 7594-7603.
15. RIGOLIN, G.M. et al. 2004. In patients withmyelodysplastic syndromes response to rHuEpo and G-CSF treatment is related to an increase of cytogenetically normal CD34+ cells. Br. J. Haematol. 126: 501-507.
16. LIST, A. et al. 2005. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352: 549-557.
17. LUBBERT, M. et al. 2001. Cytogenetic response in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114: 349-357.
18. SILVERMAN, L.R. et al. 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia study group B. J. Clin. Oncol. 20: 2429-2440.